Matthew Maenner is surveillance team lead for the National Center on Birth Defects and Developmental Disabilities at the U.S. Centers for Disease Control and Prevention.
Matthew Maenner
Surveillance team lead
National Center on Birth Defects and Developmental Disabilities
From this contributor
Q&A with Matthew Maenner: Estimating autism prevalence quickly
A new method to track autism prevalence in 11 U.S. states is twice as fast as the old approach — and yields similar results.
Q&A with Matthew Maenner: Estimating autism prevalence quickly
Explore more from The Transmitter
Gene replacement therapy normalizes some traits in SYNGAP1 model mice
The first published virus-based gene therapy for SYNGAP1 deletion yields benefits despite the gene’s long length and complexity.
Gene replacement therapy normalizes some traits in SYNGAP1 model mice
The first published virus-based gene therapy for SYNGAP1 deletion yields benefits despite the gene’s long length and complexity.
Does AI understand what it produces? Henk de Regt explores how we might assess understanding in machines and humans
Building on his philosophy of how scientists understand what they work on, de Regt is extending his approach to test understanding in machines.
Does AI understand what it produces? Henk de Regt explores how we might assess understanding in machines and humans
Building on his philosophy of how scientists understand what they work on, de Regt is extending his approach to test understanding in machines.
Role of maternal factors in autism; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 17 November.
Role of maternal factors in autism; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 17 November.